NuCana (NCNA) Return on Capital Employed (2018 - 2025)
NuCana's (NCNA) quarterly Return on Capital Employed came in at 68.47% in Q4 2025, up 19453.0% year-on-year from N/an in Q4 2024, and up 23.19% quarter-over-quarter from 89.13% in Q3 2025.
NuCana (NCNA) Return on Capital Employed (2018 - 2025) Analysis & Trends
NuCana has disclosed Return on Capital Employed across 8 years of filings, most recently posting 68.47% for Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 68.47%, up 19453.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 68.47% (up 19453.0% YoY), and the FY2025 annual result was 116.34%, up 6983.0% from the prior year.
- Return on Capital Employed came in at 68.47% for Q4 2025 at NuCana, up from 89.13% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 43.6% in Q1 2021 to a low of 672.27% in Q3 2024.
- The 5-year median for Return on Capital Employed is 98.15% (2022), against an average of 184.79%.
- Across the five-year window, Return on Capital Employed slumped 51823 bps in 2024 and jumped 58314 bps in 2025, its largest moves.
- NuCana's Return on Capital Employed stood at 66.9% in 2021, then tumbled by 38 bps to 92.63% in 2022, then sank by 91 bps to 176.79% in 2023, then sank by 49 bps to 263.0% in 2024, then jumped by 74 bps to 68.47% in 2025.
- The last three Return on Capital Employed figures came in at 68.47% (Q4 2025), 89.13% (Q3 2025), and 420.12% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -107.40% |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -50.43% |
| 10 | NuCana | 29.13 Bn | 29.13 Bn | - | -68.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -68.47% |
| Sep 30, 2025 | -89.13% |
| Jun 30, 2025 | -420.12% |
| Mar 31, 2025 | -291.42% |
| Dec 31, 2024 | -263.00% |
| Sep 30, 2024 | -672.27% |
| Jun 30, 2024 | -526.42% |
| Mar 31, 2024 | -273.36% |
| Dec 31, 2023 | -176.79% |
| Sep 30, 2023 | -154.04% |
| Jun 30, 2023 | -120.77% |
| Mar 31, 2023 | -103.68% |
| Dec 31, 2022 | -92.63% |
| Sep 30, 2022 | -76.52% |
| Jun 30, 2022 | -72.43% |
| Mar 31, 2022 | -76.76% |
| Dec 31, 2021 | -66.90% |
| Sep 30, 2021 | -57.41% |
| Jun 30, 2021 | -50.10% |
| Mar 31, 2021 | -43.60% |